logo
welcome
Reuters

Reuters

J&J discontinues dengue drug study after changes in R&D portfolio

Reuters
Summary
Nutrition label

81% Informative

Johnson & Johnson discontinue field study of its experimental pill for prevention of dengue.

Drugmaker reprioritized its communicable diseases R&D portfolio.

No safety issues were identified for the drug, mosnodenvir, the company said.

Dengue fever is also known as "break bone fever" for the severity of the joint pain and spasms some patients experience.

VR Score

91

Informative language

97

Neutral language

81

Article tone

formal

Language

English

Language complexity

68

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links